Usana Health Sciences Inc (NYSE: USNA) has a price-to-earnings ratio that is above its average at 10.84x. The stock has a 36-month beta value of 0.65. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for USNA is 11.09M, and at present, short sellers hold a 6.81% of that float. On April 18, 2025, the average trading volume of USNA was 209.40K shares.
USNA) stock’s latest price update
Usana Health Sciences Inc (NYSE: USNA)’s stock price has soared by 1.32 in relation to previous closing price of 23.43. Nevertheless, the company has seen a loss of -4.04% in its stock price over the last five trading days. prnewswire.com reported 2025-04-14 that SALT LAKE CITY, April 14, 2025 /PRNewswire/ — USANA Health Sciences, Inc., a global leader in cellular nutrition, recently conducted a clinical study on its Celavive Resurfacing Serum to evaluate the efficacy and tolerance of the product. The results showed that Resurfacing Serum was well-tolerated by all subjects and users showed statistically significant improvements in the appearance of their skin in just two weeks.
USNA’s Market Performance
Usana Health Sciences Inc (USNA) has seen a -4.04% fall in stock performance for the week, with a -13.80% decline in the past month and a -30.42% plunge in the past quarter. The volatility ratio for the week is 3.68%, and the volatility levels for the past 30 days are at 4.07% for USNA. The simple moving average for the past 20 days is -7.92% for USNA’s stock, with a -34.08% simple moving average for the past 200 days.
Analysts’ Opinion of USNA
Jefferies, on the other hand, stated in their research note that they expect to see USNA reach a price target of $53, previously predicting the price at $78. The rating they have provided for USNA stocks is “Underperform” according to the report published on July 07th, 2022.
DA Davidson gave a rating of “Neutral” to USNA, setting the target price at $86 in the report published on April 14th of the previous year.
USNA Trading at -17.59% from the 50-Day Moving Average
After a stumble in the market that brought USNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.31% of loss for the given period.
Volatility was left at 4.07%, however, over the last 30 days, the volatility rate increased by 3.68%, as shares sank -13.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.61% lower at present.
During the last 5 trading sessions, USNA fell by -4.04%, which changed the moving average for the period of 200-days by -47.06% in comparison to the 20-day moving average, which settled at $25.78. In addition, Usana Health Sciences Inc saw -33.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at USNA starting from Foukas Joshua, who sale 5,732 shares at the price of $32.54 back on Mar 12 ’25. After this action, Foukas Joshua now owns 0 shares of Usana Health Sciences Inc, valued at $186,514 using the latest closing price.
Neidig Brent, the CHIEF COMMERCIAL OFFICER of Usana Health Sciences Inc, sale 4,743 shares at $32.34 during a trade that took place back on Mar 12 ’25, which means that Neidig Brent is holding 0 shares at $153,387 based on the most recent closing price.
Stock Fundamentals for USNA
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.81 for the gross margin
The net margin for Usana Health Sciences Inc stands at 0.05. The total capital return value is set at 0.11. Equity return is now at value 7.76, with 6.09 for asset returns.
Based on Usana Health Sciences Inc (USNA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 2.1. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 236.03.
Currently, EBITDA for the company is 98.86 million with net debt to EBITDA at -1.58. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 103.92for trailing twelve months and the total asset turnover is 1.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To sum up, Usana Health Sciences Inc (USNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
